Nazanin Zeinali Nezhad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nazanin Zeinali Nezhad has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Amirhossein Shahpar
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman, Iran
7 shared publications- Aazam Gholami Shahrebabak
Department of Pediatrics, School of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Amirhossein Shahpar
Gastroenterology and Hepatology Research Center Institute of Basic and Clinical Physiology Sciences Kerman Iran
2 shared publications Mana Khazaeli
Clinical Research Development Unit, Afzalipour Hospital Kerman University of Medical Sciences Kerman Iran
2 shared publicationsMaryam Gholami Shahrebabak
Department of Pediatrics, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publicationsMehrdad Farrokhnia
Infectious and Tropical Research Center Kerman University of Medical Sciences Kerman Iran
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70555
Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report
Background: Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features resembling neuroendocrine tumors of other anatomical sites. Case Presentation: A 61‐year‐old postmenopausal female presented with a palpable left breast mass. Clinical examination revealed a 2 × 3 cm firm, poorly circumscribed mass at the 9 o'clock position with multiple satellite lesions and a solitary axillary lymph node measuring 1.5 × 1.5 cm with rubbery consistency. Sonographic evaluation demonstrated a hypoechoic mass with spiculated margins, heterogeneous echotexture, and posterior acoustic shadowing, classified as BI‐RADS 6. Core needle biopsy yielded an initial diagnosis of infiltrative ductal carcinoma, grade III, with immunohistochemistry demonstrating ER+/PR+/HER2‐ status and a Ki‐67 index of 22%. Following modified radical mastectomy, comprehensive histopathological examination revealed distinctive neuroendocrine morphology with diffuse positivity for synaptophysin and chromogranin A, confirming the diagnosis of primary neuroendocrine carcinoma of the breast, grade 2, T2N0M0. The patient underwent multimodal therapy comprising modified radical mastectomy with sentinel lymph node biopsy (all 17 nodes negative), adjuvant anthracycline‐taxane chemotherapy, chest wall radiation (50 Gy in 25 fractions), and endocrine therapy with anastrozole. Conclusion: This case highlights the diagnostic challenges of NECB, which frequently mimics conventional breast carcinoma on initial assessment. The diagnostic discordance between core biopsy and final pathology underscores the imperative for comprehensive immunohistochemical evaluation in morphologically suggestive cases. Management strategies integrate established breast cancer protocols with neuroendocrine‐specific considerations, though optimal treatment paradigms remain incompletely defined due to the paucity of dedicated clinical trials for this rare entity.
- 19 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70555
Open AccessPrimary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report
Background: Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features resembling neuroendocrine tumors of other anatomical sites. Case Presentation: A 61‐year‐old postmenopausal female presented with a palpable left breast mass. Clinical examination revealed a 2 × 3 cm firm, poorly circumscribed mass at the 9 o'clock position with multiple satellite lesions and a solitary axillary lymph node measuring 1.5 × 1.5 cm with rubbery consistency. Sonographic evaluation demonstrated a hypoechoic mass with spiculated margins, heterogeneous echotexture, and posterior acoustic shadowing, classified as BI‐RADS 6. Core needle biopsy yielded an initial diagnosis of infiltrative ductal carcinoma, grade III, with immunohistochemistry demonstrating ER+/PR+/HER2‐ status and a Ki‐67 index of 22%. Following modified radical mastectomy, comprehensive histopathological examination revealed distinctive neuroendocrine morphology with diffuse positivity for synaptophysin and chromogranin A, confirming the diagnosis of primary neuroendocrine carcinoma of the breast, grade 2, T2N0M0. The patient underwent multimodal therapy comprising modified radical mastectomy with sentinel lymph node biopsy (all 17 nodes negative), adjuvant anthracycline‐taxane chemotherapy, chest wall radiation (50 Gy in 25 fractions), and endocrine therapy with anastrozole. Conclusion: This case highlights the diagnostic challenges of NECB, which frequently mimics conventional breast carcinoma on initial assessment. The diagnostic discordance between core biopsy and final pathology underscores the imperative for comprehensive immunohistochemical evaluation in morphologically suggestive cases. Management strategies integrate established breast cancer protocols with neuroendocrine‐specific considerations, though optimal treatment paradigms remain incompletely defined due to the paucity of dedicated clinical trials for this rare entity.
- Open Access
- 10 March 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 152
Descriptive analysis of common causes of upper gastrointestinal bleeding in pediatric patients in Kerman: a study from 2022 to 2023
Upper gastrointestinal bleeding (UGIB) in pediatric patients is a significant clinical concern requiring prompt diagnosis and management. This study aims to provide a descriptive analysis of the common causes of UGIB in pediatric patients in Kerman, Iran. A cross-sectional study was conducted at Afzalipour Hospital, Kerman, from January 2022 to December 2023. All pediatric patients under 18 years with UGIB were included. Data on demographics, clinical presentation, and endoscopic findings were collected and analyzed. A total of 120 patients were included, with a mean age of 8.8 ± 4.7 years. Hematemesis was the predominant presenting feature (57.5%). All patients underwent endoscopy, with a diagnostic yield of 88.4%. Gastric erosion was the most common cause of UGIB (33.3%), followed by esophageal varices (13.3%). The etiology varied across age groups, with Mallory-Weiss syndrome being the second most common cause in infants. Blood transfusion was required in 31.67% of patients. This study highlights the common causes and clinical features of pediatric UGIB in Kerman, Iran. Gastric erosion (33.3%) was the most frequent cause, and endoscopy achieved a high diagnostic yield (88.4%). Blood transfusion was necessary in 31.67% of patients. These findings emphasize the need for age-specific diagnostic strategies and reflect regional differences in UGIB etiology.
- 10 March 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 152
Open AccessDescriptive analysis of common causes of upper gastrointestinal bleeding in pediatric patients in Kerman: a study from 2022 to 2023
Upper gastrointestinal bleeding (UGIB) in pediatric patients is a significant clinical concern requiring prompt diagnosis and management. This study aims to provide a descriptive analysis of the common causes of UGIB in pediatric patients in Kerman, Iran. A cross-sectional study was conducted at Afzalipour Hospital, Kerman, from January 2022 to December 2023. All pediatric patients under 18 years with UGIB were included. Data on demographics, clinical presentation, and endoscopic findings were collected and analyzed. A total of 120 patients were included, with a mean age of 8.8 ± 4.7 years. Hematemesis was the predominant presenting feature (57.5%). All patients underwent endoscopy, with a diagnostic yield of 88.4%. Gastric erosion was the most common cause of UGIB (33.3%), followed by esophageal varices (13.3%). The etiology varied across age groups, with Mallory-Weiss syndrome being the second most common cause in infants. Blood transfusion was required in 31.67% of patients. This study highlights the common causes and clinical features of pediatric UGIB in Kerman, Iran. Gastric erosion (33.3%) was the most frequent cause, and endoscopy achieved a high diagnostic yield (88.4%). Blood transfusion was necessary in 31.67% of patients. These findings emphasize the need for age-specific diagnostic strategies and reflect regional differences in UGIB etiology.
- Open Access
- 29 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
From mammary mystery to parasitic surprise: a rare case of primary breast hydatid cyst
Primary breast hydatid cyst is an exceedingly rare manifestation of echinococcosis, with an incidence of less than 0.27% among all hydatid cyst cases. This report presents a unique case of a 51-year-old multiparous female who initially presented with a painless left breast mass. Initial imaging studies, including ultrasonography and mammography, revealed a 4.5 × 4 cm cyst classified as BI-RADS 3. The cyst was initially managed with fine-needle aspiration and conservative treatment. However, it recurred twice over a six-month period, necessitating surgical excision. Preoperative laboratory work ups revealed eosinophilia, a finding initially overlooked but later recognized as significant. Histopathological examination of the excised specimen confirmed the diagnosis of a hydatid cyst. Post-surgical management included albendazole therapy, regular imaging follow-ups, and patient education on hygiene practices to prevent reinfection. This case highlights the importance of considering parasitic etiologies in the differential diagnosis of breast masses, particularly in endemic regions. It also underscores the value of a multidisciplinary approach in managing such rare cases. The unexpected diagnosis of a primary breast hydatid cyst in this case serves as a reminder of the diverse presentations of echinococcosis and the need for heightened clinical suspicion in atypical breast lesions. Not applicable.
- 29 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Open AccessFrom mammary mystery to parasitic surprise: a rare case of primary breast hydatid cyst
Primary breast hydatid cyst is an exceedingly rare manifestation of echinococcosis, with an incidence of less than 0.27% among all hydatid cyst cases. This report presents a unique case of a 51-year-old multiparous female who initially presented with a painless left breast mass. Initial imaging studies, including ultrasonography and mammography, revealed a 4.5 × 4 cm cyst classified as BI-RADS 3. The cyst was initially managed with fine-needle aspiration and conservative treatment. However, it recurred twice over a six-month period, necessitating surgical excision. Preoperative laboratory work ups revealed eosinophilia, a finding initially overlooked but later recognized as significant. Histopathological examination of the excised specimen confirmed the diagnosis of a hydatid cyst. Post-surgical management included albendazole therapy, regular imaging follow-ups, and patient education on hygiene practices to prevent reinfection. This case highlights the importance of considering parasitic etiologies in the differential diagnosis of breast masses, particularly in endemic regions. It also underscores the value of a multidisciplinary approach in managing such rare cases. The unexpected diagnosis of a primary breast hydatid cyst in this case serves as a reminder of the diverse presentations of echinococcosis and the need for heightened clinical suspicion in atypical breast lesions. Not applicable.
- Open Access
- 22 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9564
Diagnostic Dilemma: Investigating Respiratory Symptoms in a Middle‐Aged Smoker
This case report presents a diagnostic challenge encountered in a 65‐year‐old male admitted with fever, dyspnea, chest pain, and hemoptysis, alongside constitutional symptoms including weight loss, night sweats, and fatigue. Despite initial suspicion for pulmonary thromboembolism and empirical antibiotic therapy for pneumonia, subsequent bronchoscopic evaluation revealed acute necrotizing granulomatous bronchitis, strongly indicative of endobronchial tuberculosis (TB). This diagnosis emphasizes the importance of considering TB in patients with chronic respiratory symptoms, particularly in high‐risk populations. Management involves initiating multidrug antitubercular therapy, close monitoring, infection control measures, and patient education. Prompt diagnosis and appropriate management are crucial in optimizing outcomes and reducing disease burden in TB.
- 22 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9564
Open AccessDiagnostic Dilemma: Investigating Respiratory Symptoms in a Middle‐Aged Smoker
This case report presents a diagnostic challenge encountered in a 65‐year‐old male admitted with fever, dyspnea, chest pain, and hemoptysis, alongside constitutional symptoms including weight loss, night sweats, and fatigue. Despite initial suspicion for pulmonary thromboembolism and empirical antibiotic therapy for pneumonia, subsequent bronchoscopic evaluation revealed acute necrotizing granulomatous bronchitis, strongly indicative of endobronchial tuberculosis (TB). This diagnosis emphasizes the importance of considering TB in patients with chronic respiratory symptoms, particularly in high‐risk populations. Management involves initiating multidrug antitubercular therapy, close monitoring, infection control measures, and patient education. Prompt diagnosis and appropriate management are crucial in optimizing outcomes and reducing disease burden in TB.
- Open Access
- 10 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0309940
Early vs. delayed QTc prolongation in acute poisoning: A prognostic accuracy study—A case series
Given the limited capacity of intensive care units in many countries, it is crucial to identify reliable prognostic markers to optimize poisoning patients management and improve outcomes. This study aimed to assess the predictive value of three variables, namely the initial QTc interval (iQTc) measured within two hours of admission, the delayed QTc interval (dQTc) measured between 6 and 12 hours of entry, and the QTc interval trend over time (ΔQTc), for mortality in patients with undifferentiated poisoning. A retrospective case series was conducted on 70 patients with undifferentiated poisoning admitted to the intensive care unit (ICU) of Afzalipour Hospital between March 21, 2021, and March 20, 2023. The results of the multivariate analysis revealed that dQTc, base deficit, and creatinine were independently associated with mortality (P value < 0.001). The dQTc had the highest predictive ability, with an area under the curve (AUC) of 0.84, followed by ΔQTc with an AUC of 0.76, and iQTc with an AUC of 0.67. Additionally, the results of the Generalized Estimating Equation model with repeated measurements revealed a higher odds ratio for dQTc (OR, 6.33; 95% CI, 2.54–15.79) compared to iQTc (OR, 4.92; 95% CI, 1.71–14.17). The study concluded that monitoring the dQTc interval could provide valuable prognostic information in acute poisoning cases.
- 10 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0309940
Open AccessEarly vs. delayed QTc prolongation in acute poisoning: A prognostic accuracy study—A case series
Given the limited capacity of intensive care units in many countries, it is crucial to identify reliable prognostic markers to optimize poisoning patients management and improve outcomes. This study aimed to assess the predictive value of three variables, namely the initial QTc interval (iQTc) measured within two hours of admission, the delayed QTc interval (dQTc) measured between 6 and 12 hours of entry, and the QTc interval trend over time (ΔQTc), for mortality in patients with undifferentiated poisoning. A retrospective case series was conducted on 70 patients with undifferentiated poisoning admitted to the intensive care unit (ICU) of Afzalipour Hospital between March 21, 2021, and March 20, 2023. The results of the multivariate analysis revealed that dQTc, base deficit, and creatinine were independently associated with mortality (P value < 0.001). The dQTc had the highest predictive ability, with an area under the curve (AUC) of 0.84, followed by ΔQTc with an AUC of 0.76, and iQTc with an AUC of 0.67. Additionally, the results of the Generalized Estimating Equation model with repeated measurements revealed a higher odds ratio for dQTc (OR, 6.33; 95% CI, 2.54–15.79) compared to iQTc (OR, 4.92; 95% CI, 1.71–14.17). The study concluded that monitoring the dQTc interval could provide valuable prognostic information in acute poisoning cases.
- Open Access
- 25 August 2024
- Published by Wiley
Diagnostic Dilemma: Investigating Respiratory Symptoms in a Middle-aged Smoker
- 25 August 2024
- Published by Wiley
Open AccessDiagnostic Dilemma: Investigating Respiratory Symptoms in a Middle-aged Smoker
- 7 August 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (6) , 1218-1232
Safety and Efficacy of Geraniol in Gastrointestinal System
- 7 August 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (6) , 1218-1232
Safety and Efficacy of Geraniol in Gastrointestinal System
- Open Access
- 6 April 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (8) , 2636-2643
Topical isoniazid as a novel treatment for melasma: A randomized, double‐blind, vehicle‐controlled clinical trial
Introduction: Melasma is a chronic hyperpigmentation disorder, and its treatment poses a challenge to dermatologists due to its chronicity and resistance to conventional therapies. Oral isoniazid is used for the treatment of tuberculosis. One of us had previously showed that topical isoniazid exerts a strong depigmenting action in animal models. In this clinical trial, we assessed the therapeutic effect of topical isoniazid on melasma.Methods: Twenty female patients suffering from epidermal melasma were enrolled and divided equally into two groups. The treatment group received topical isoniazid 10%, and the control group received the cold cream vehicle as the placebo. All participants were advised to avoid sunlight and used SPF 50 sunscreen. Patients applied topical agents once daily at night for 3 months. The melanin and erythema indices were measured by colorimetric evaluations at baseline and after 4, 8, and 12 weeks of treatment. At these time points, the (mMASI) score was also determined, as was the subjective evaluation through Melasma Quality of Life Scale (MELASQOL) scores. Blood tests were performed to evaluate CBC and the liver enzymes.Results: All patients completed the 12‐week study. In the treatment group, a significant decrease in melanin index from 63.77 ± 6.27 at baseline to 55.92 ± 5.79 was recorded (p = 0.001). Very minimal clinical changes were also seen in the control group and melanin index was decreased from 62.65 ± 2.23 to 61.25 ± 2.34 (p = 0.004). Clinically significant differences were observed in the rate of changes between both groups. These findings indicate that topical isoniazid has significant depigmenting effects compared to the placebo (p = 0.001). The erythema index remained unchanged in both groups. In the treatment group, the mMASI score was 5.63 ± 3.28 at baseline and 2.13 ± 1.71 at the last follow‐up, significantly reduced compared to the control group (p = 0.002). The MELASQOL score indicated a significant improvement in the quality of life in the treatment group.Conclusion: This clinical trial shows for the first time that topical isoniazid is effective in treating melasma. Further clinical trials are necessary to confirm the efficacy and tolerability of topical isoniazid in comparison with other skin‐depigmenting compounds.
- 6 April 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (8) , 2636-2643
Open AccessTopical isoniazid as a novel treatment for melasma: A randomized, double‐blind, vehicle‐controlled clinical trial
Introduction: Melasma is a chronic hyperpigmentation disorder, and its treatment poses a challenge to dermatologists due to its chronicity and resistance to conventional therapies. Oral isoniazid is used for the treatment of tuberculosis. One of us had previously showed that topical isoniazid exerts a strong depigmenting action in animal models. In this clinical trial, we assessed the therapeutic effect of topical isoniazid on melasma.Methods: Twenty female patients suffering from epidermal melasma were enrolled and divided equally into two groups. The treatment group received topical isoniazid 10%, and the control group received the cold cream vehicle as the placebo. All participants were advised to avoid sunlight and used SPF 50 sunscreen. Patients applied topical agents once daily at night for 3 months. The melanin and erythema indices were measured by colorimetric evaluations at baseline and after 4, 8, and 12 weeks of treatment. At these time points, the (mMASI) score was also determined, as was the subjective evaluation through Melasma Quality of Life Scale (MELASQOL) scores. Blood tests were performed to evaluate CBC and the liver enzymes.Results: All patients completed the 12‐week study. In the treatment group, a significant decrease in melanin index from 63.77 ± 6.27 at baseline to 55.92 ± 5.79 was recorded (p = 0.001). Very minimal clinical changes were also seen in the control group and melanin index was decreased from 62.65 ± 2.23 to 61.25 ± 2.34 (p = 0.004). Clinically significant differences were observed in the rate of changes between both groups. These findings indicate that topical isoniazid has significant depigmenting effects compared to the placebo (p = 0.001). The erythema index remained unchanged in both groups. In the treatment group, the mMASI score was 5.63 ± 3.28 at baseline and 2.13 ± 1.71 at the last follow‐up, significantly reduced compared to the control group (p = 0.002). The MELASQOL score indicated a significant improvement in the quality of life in the treatment group.Conclusion: This clinical trial shows for the first time that topical isoniazid is effective in treating melasma. Further clinical trials are necessary to confirm the efficacy and tolerability of topical isoniazid in comparison with other skin‐depigmenting compounds.
- Open Access
- 1 April 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (4) , e8697
Empyema necessitans as a rare manifestation of Staphylococcus aureus
Key Clinical Message: Empyema necessitans (EN) is a rare complication of empyema, in which pus accumulates within the pleural space and spreads through the chest wall, leading to the formation of a subcutaneous abscess. This condition presents significant diagnostic and therapeutic challenges due to its rarity and potential for serious complications. Here, we present the case of an 8‐year‐old boy with a history of parapneumonic effusion that was incompletely treated due to a lack of fibrinolytic agent injection. He presented with fever, chills, a productive cough, and left‐sided chest pain with yellowish purulent secretions from the left chest wall. The patient was diagnosed with EN caused by Staphylococcus aureus , which has occurred due to inadequate treatment and the lack of administration of a fibrinolytic agent injection for the patient. He was treated with broad‐spectrum antibiotics, video‐assisted thoracic surgery, and a chest tube for complete drainage. The patient showed a smooth and uneventful recovery, highlighting the importance of early diagnosis and prompt treatment of EN to avoid further complications. This case report aims to increase awareness among clinicians about the importance of early recognition and appropriate management of EN to improve patient outcomes.
- 1 April 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (4) , e8697
Open AccessEmpyema necessitans as a rare manifestation of Staphylococcus aureus
Key Clinical Message: Empyema necessitans (EN) is a rare complication of empyema, in which pus accumulates within the pleural space and spreads through the chest wall, leading to the formation of a subcutaneous abscess. This condition presents significant diagnostic and therapeutic challenges due to its rarity and potential for serious complications. Here, we present the case of an 8‐year‐old boy with a history of parapneumonic effusion that was incompletely treated due to a lack of fibrinolytic agent injection. He presented with fever, chills, a productive cough, and left‐sided chest pain with yellowish purulent secretions from the left chest wall. The patient was diagnosed with EN caused by Staphylococcus aureus , which has occurred due to inadequate treatment and the lack of administration of a fibrinolytic agent injection for the patient. He was treated with broad‐spectrum antibiotics, video‐assisted thoracic surgery, and a chest tube for complete drainage. The patient showed a smooth and uneventful recovery, highlighting the importance of early diagnosis and prompt treatment of EN to avoid further complications. This case report aims to increase awareness among clinicians about the importance of early recognition and appropriate management of EN to improve patient outcomes.
- Open Access
- 3 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 1956-1963
A review of isotretinoin in the treatment of frontal fibrosing alopecia
Introduction: Frontal fibrosing alopecia (FFA) is characterized by scarring alopecia of the frontotemporal scalp and facial papules. Isotretinoin is a vitamin A‐derived retinoid discovered in 1955 and approved for treating nodulocystic acne. This drug can also affect facial papules and frontotemporal hair loss in patients with FFA. In this article, we conducted a review of the available studies investigating the use of oral isotretinoin for FFA treatment. Our study provides insights into the efficacy and safety of isotretinoin as a potential treatment option for FFA and highlights areas for future research.Method: In this study, we aimed to investigate the potential advantages and disadvantages of isotretinoin as a treatment for FFA. To identify all relevant articles, we developed a comprehensive search strategy and conducted a thorough search of three major databases: PubMed, Embase, and Science Direct. We retrieved a total of 82 articles from the search results. Two independent reviewers then screened each of the 82 articles based on our inclusion and exclusion criteria, resulting in the identification of 15 articles that were deemed relevant to our study.Results: Across the 15 articles, 232 patients who suffered from FFA were involved. Nearly 90% of patients experienced a significant reduction of symptoms after receiving oral isotretinoin at 10–40 mg daily. We conclude that isotretinoin can positively affect facial papules and help suppress hair loss.
- 3 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 1956-1963
Open AccessA review of isotretinoin in the treatment of frontal fibrosing alopecia
Introduction: Frontal fibrosing alopecia (FFA) is characterized by scarring alopecia of the frontotemporal scalp and facial papules. Isotretinoin is a vitamin A‐derived retinoid discovered in 1955 and approved for treating nodulocystic acne. This drug can also affect facial papules and frontotemporal hair loss in patients with FFA. In this article, we conducted a review of the available studies investigating the use of oral isotretinoin for FFA treatment. Our study provides insights into the efficacy and safety of isotretinoin as a potential treatment option for FFA and highlights areas for future research.Method: In this study, we aimed to investigate the potential advantages and disadvantages of isotretinoin as a treatment for FFA. To identify all relevant articles, we developed a comprehensive search strategy and conducted a thorough search of three major databases: PubMed, Embase, and Science Direct. We retrieved a total of 82 articles from the search results. Two independent reviewers then screened each of the 82 articles based on our inclusion and exclusion criteria, resulting in the identification of 15 articles that were deemed relevant to our study.Results: Across the 15 articles, 232 patients who suffered from FFA were involved. Nearly 90% of patients experienced a significant reduction of symptoms after receiving oral isotretinoin at 10–40 mg daily. We conclude that isotretinoin can positively affect facial papules and help suppress hair loss.